Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

NCT ID: NCT07041801

Last Updated: 2025-06-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-28
• Study Completion Date: 2027-12-28

Brief Summary

This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.

Detailed Description

Inclusion criteria:

1. Fully understand the purpose, nature, methods of the trial, as well as possible adverse reactions, voluntarily participate as a subject, and sign the informed consent form.

2. Age 18-65 years old (inclusive of the boundaries, based on the date of signing the informed consent form), regardless of gender;

3. The subjects (both male and female) must agree not to have a reproductive plan during the trial period and after the injection administration for at least 12 months, and voluntarily take effective contraceptive measures with their partners (see Appendix 1), and have no plans for sperm donation or egg donation;

4. According to the diagnostic classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) in 2019, diagnosed with systemic lupus erythematosus (SLE);

Conditions

Systemic Lupus Erythematosus (SLE)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

hUC-MSCs treatment (low dose)

Conventional plus hUC-MSCs treatment (low dose)

Group Type: EXPERIMENTAL

hUC-MSCs treatment (low dose)

Intervention Type: DRUG

patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.

hUC-MSCs treatment （medium dose）

conventional therapy plus hUC-MSCs treatment （medium dose）

Group Type: EXPERIMENTAL

hUC-MSCs treatment (medium dose)

Intervention Type: BIOLOGICAL

patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.

hUC-MSCs treatment （high dose）

conventional therapy plus hUC-MSCs treatment （high dose）

Group Type: EXPERIMENTAL

hUC-MSCs treatment (high dose)

Intervention Type: BIOLOGICAL

patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.

hUC-MSCs treatment （Double dose）

conventional therapy plus hUC-MSCs treatment（Double dose）

Group Type: EXPERIMENTAL

hUC-MSCs treatment （Double dose）

Intervention Type: BIOLOGICAL

Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.

Placebo

conventional therapy plus Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

patients will receive conventional therapy plus Placebo

Interventions

hUC-MSCs treatment (low dose)

patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.

Intervention Type: DRUG

hUC-MSCs treatment (medium dose)

patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.

Intervention Type: BIOLOGICAL

hUC-MSCs treatment (high dose)

patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.

Intervention Type: BIOLOGICAL

Placebo

patients will receive conventional therapy plus Placebo

Intervention Type: DRUG

hUC-MSCs treatment （Double dose）

Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.

Intervention Type: BIOLOGICAL

Other Intervention Names

MSC-medium; MSC-high

Eligibility Criteria

Inclusion Criteria

1. Fully understand the purpose, nature, methods of the trial and possible adverse reactions, voluntarily become a subject, and sign the informed consent form.

2. Age 18-65 years old (inclusive of the boundary values, based on the time of signing the informed consent form), no gender restrictions;

3. The subjects (male and female) must agree not to have a reproductive plan during the trial period and after the injection administration for at least 12 months, and voluntarily take effective contraceptive measures with their partners (see Appendix 1), and have no plans for sperm donation or egg donation;

4. According to the diagnostic classification criteria of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) in 2019, diagnosed with systemic lupus erythematosus (SLE);

5. Meet one of the following conditions: the antinuclear antibody (ANA) is positive at 1:80 during screening or the anti-dsDNA antibody is positive during screening or the anti-Sm antibody is positive during screening;

Exclusion Criteria

1. Those who are judged by the researchers to be likely to be allergic to the investigational drug or any component thereof;

2. Those who have had central nervous system diseases within 8 weeks before administration (including but not limited to epilepsy, mental illness, interstitial encephalopathy syndrome, stroke, encephalitis, central nervous system vasculitis, etc.);

3. Those who have undergone major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplantation;

4. Those who have any major diseases/diseases or unstable clinical conditions (such as liver, kidney, hematological, endocrine, pulmonary, immune, mental, etc.) or active infections/infectious diseases with evidence, and according to the researchers' clinical judgment, if the subjects participate in the study, it will significantly increase the risks for the subjects;

5. Those who currently have known or suspected malignant tumors;

6. Those who have severe pulmonary arterial hypertension (>70 mmHg, 1 mmHg = 0.133 kPa), or mild to moderate pulmonary arterial hypertension patients with severe cardiopulmonary insufficiency;

7. Those who have antiphospholipid syndrome (APS), or have a history of catastrophic antiphospholipid syndrome (CAPS), or although not diagnosed as APS, but are evaluated by the researchers as having an increased risk of thrombosis;

8. Those who have herpes zoster infection within 90 days before administration, or any infection that requires hospitalization treatment or intravenous or intramuscular injection of antibiotics within 60 days before administration;

9. Those who have undergone major surgical operations within 28 days before administration, or those who are expected to undergo major surgical operations during the trial;

10. Subjects who have positive serological tests for viral hepatitis during the screening period, positive human immunodeficiency virus antibody (HIV-Ab), positive hepatitis B surface antigen (HBsAg), positive hepatitis C antibody (HCV-Ab), or positive Treponema pallidum antibody (TP-Ab);

11. Other situations that the researchers consider may affect the subjects' willingness to provide informed consent or follow the trial protocol, or situations where the subjects' participation in the trial may affect the trial results or their own safety.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shenzhen Beike Bio-Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shenzhen Beike Bio-Technology Co. Ltd.

Shenzhen, Guangdong, China

Site Status: RECRUITING

Countries

China

Facility Contacts

HU

Role: primary

guotao@beike.cc

+86-0755-86309200

Other Identifiers

BK-SLE-I/01

Identifier Type: -

Identifier Source: org_study_id